Scarica l'app Stockscreener
1.20
0.00%
0.00
Synlogic Inc Borsa (SYBX) Ultime notizie
Phenylktonuria Pipeline 2025: Therapies, MOA Insights, and Key - openPR.com
Phenylktonuria Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Erytech Pharma SA, Homology Medicines Inc., Synlogic Inc., BioMarin Pharmaceuticals - Barchart.com
Synlogic's executive sells shares worth $2,802 - MSN
5 Best Microbiome Companies (June 2025) - Securities.io
Synlogic Inc. Reports Strategic Shift and Positive Earnings - TipRanks
Synlogic (NASDAQ:SYBX) Stock Passes Below Two Hundred Day Moving Average – What’s Next? - Defense World
Synlogic (SNDX) to Attend Meeting Hosted by B. Riley in New York - GuruFocus
Synlogic (SYBX) Projected to Post Earnings on Tuesday - Defense World
Gene Circuits Market on the Rise with Advancements in Synthetic Biology | Synlogic, Synthego, Ginkgo Bioworks - openPR.com
Renaissance Technologies LLC Decreases Stake in Synlogic, Inc. (NASDAQ:SYBX) - Defense World
Synlogic’s executive Mary Beth Dooley sells $172 in common stock - Investing.com Australia
Synlogic’s executive Mary Beth Dooley sells $172 in common stock By Investing.com - Investing.com UK
SYBX stock touches 52-week low at $1.14 amid market challenges - Investing.com India
The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors - Business Wire
Gallium Arsenide Market Applications and Semiconductor Industry Impact - openPR.com
Synlogic (NASDAQ:SYBX) Shares Pass Below Fifty Day Moving Average – Here’s Why - Defense World
SYBX stock touches 52-week low at $1.15 amid market challenges - Investing.com Australia
Synlogic (SYBX) to Release Quarterly Earnings on Tuesday - Defense World
Synlogic Inc. (SYBX) reports earnings - Quartz
Week Ahead (Nov.2226): FDA Decision, Data Presentations (ABEO, SYBX, AADI…) - RTTNews
CRISPR and Cas Gene Market May Set a New Epic Growth Story | Fate Therapeutics, Cellectis, Synlogic - Newstrail
Microbiomes Market to Grow by USD 824.3 Million (2025-2029) with Rising Disease Prevalence Boosting the Market, Report on How AI is Redefining Market LandscapeTechnavio - The Malaysian Reserve
Synlogic's executive sells shares worth $2,802 By Investing.com - Investing.com South Africa
Promising Growth Expected in Gout Therapeutics Market, Set to Reach $5.03 Billion by 2029 with a CAGR of 11.7% - WhaTech
Synlogic (SYBX) Stock Price, News & Analysis - MarketBeat
Synlogic announces board member resignation By Investing.com - Investing.com Canada
Synlogic announces board member resignation - Investing.com
The definitive Boston biotech layoff tracker for 2024 - The Business Journals
Biopolymers Market to Reach USD 47.4 Billion by 2032 Driven - GlobeNewswire
Only the paranoid survive, and the CEO’s paradox, from Aoife Brennan - BioCentury
Urea Cycle Disorder Treatment Market to Grow by USD 215.4 Million (2024-2028), Driven by Rising Prevalence, with AI Redefining Market LandscapeTechnavio - PR Newswire
Phenylketonuria Market size is ~700 USD million in 2023, asserts DelveInsight | Pharma Giants: PTC Therapeutics, Homology Medicines, Synlogic, BioMarin Pharmaceuticals - The Globe and Mail
Synlogic Third Quarter 2024 Earnings: US$0.01 loss per share (vs US$2.57 loss in 3Q 2023) - Yahoo Finance
Synlogic Reports Third Quarter 2024 Financial Results - GlobeNewswire
The 2024 Biotech Graveyard - Fierce Biotech
Synlogic's head of finance Mary Beth Dooley sells $110 in stock - Investing.com
(PDF) The effects of caffeinated and decaffeinated coffee on sex hormone-binding globulin and endogenous sex hormone levels: A randomized controlled trial - ResearchGate
Oxygen Scavenger Market Set to Reach USD 8.2 Billion by - GlobeNewswire
Synlogic Reports Second Quarter 2024 Financial Results - GlobeNewswire
Xilio Therapeutics Appoints Aoife Brennan and James Shannon to its Board of Directors - citybiz
Gut Microbiota Market Set to Reach a Staggering US$ 3,600.1 Million by 2032 - BioSpace
Synlogic Reports First Quarter 2024 Financial Results - GlobeNewswire
Designer Genes: Synlogic Is Crafting Living Therapeutics Programmed to Treat Disease: - Mary Ann Liebert, Inc.
Human Microbiome Market Size & Share to Surpass USD 2,555 million by 2030 - WhaTech
Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results - GlobeNewswire
Synlogic Adopts Limited Duration Stockholders Rights Plan - GlobeNewswire
Irish-led Synlogic to cease operations after ending drug trial - Silicon Republic
Synlogic Announces Plan to Cease Operations and Reduce Its Workforce by More Than 90% - SynBioBeta
Synlogic shuts down after PKU drug fails phase 3 trial - pharmaphorum
Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update - Yahoo Finance
Synlogic Announces Publication of Preclinical and Clinical - GlobeNewswire
0.34%
7.69%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):